These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 26727639)

  • 21. Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low-middle-income country.
    Lins MM; Mello MJG; Ribeiro RC; De Camargo B; de Fátima Pessoa Militão de Albuquerque M; Thuler LCS
    Ann Hematol; 2019 Jun; 98(6):1403-1411. PubMed ID: 30915498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group.
    Gerbing RB; Alonzo TA; Sung L; Gamis AS; Meshinchi S; Plon SE; Bertuch AA; Gramatges MM
    J Clin Oncol; 2016 Nov; 34(31):3766-3772. PubMed ID: 27354474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low incidence of sepsis due to viridans streptococci in a ten-year retrospective study of pediatric acute myeloid leukemia.
    Brunet AS; Ploton C; Galambrun C; Pondarré C; Pages MP; Bleyzac N; Freydière AM; Barbé G; Bertrand Y
    Pediatr Blood Cancer; 2006 Nov; 47(6):765-72. PubMed ID: 16333838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia.
    Gillis S; Dann EJ; Rund D
    Am J Hematol; 1996 Jan; 51(1):26-31. PubMed ID: 8571934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia.
    Miller TP; Li Y; Kavcic M; Troxel AB; Huang YS; Sung L; Alonzo TA; Gerbing R; Hall M; Daves MH; Horton TM; Pulsipher MA; Pollard JA; Bagatell R; Seif AE; Fisher BT; Luger S; Gamis AS; Adamson PC; Aplenc R
    J Clin Oncol; 2016 May; 34(13):1537-43. PubMed ID: 26884558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of fluid overload and infection on respiratory adverse event development during induction therapy for childhood acute myeloid leukemia.
    Miller LH; Keller F; Mertens A; Klein M; Allen K; Castellino S; Woods WG
    Pediatr Blood Cancer; 2019 Dec; 66(12):e27975. PubMed ID: 31502412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Description of PICU Unplanned Readmission.
    Kotsakis A; Stevens D; Frndova H; Neal R; Williamson G; Mohseni-Bod H; Parshuram CS
    Pediatr Crit Care Med; 2016 Jun; 17(6):558-62. PubMed ID: 27261644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
    Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
    J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The feasibility of an early hospital discharge following chemotherapy for the acute myeloid leukemia.
    Sopko L; Sabty FA; Rimajova V; Roziakova L; Elanova A; Demeckova E; Mistrik M
    Bratisl Lek Listy; 2012; 113(5):298-300. PubMed ID: 22616589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01.
    De Moerloose B; Reedijk A; de Bock GH; Lammens T; de Haas V; Denys B; Dedeken L; van den Heuvel-Eibrink MM; Te Loo M; Uyttebroeck A; Van Damme A; Van der Werff-Ten Bosch J; Zsiros J; Kaspers G; de Bont E
    Pediatr Blood Cancer; 2019 May; 66(5):e27605. PubMed ID: 30623572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group.
    Sung L; Aplenc R; Alonzo TA; Gerbing RB; Lehrnbecher T; Gamis AS
    Blood; 2013 May; 121(18):3573-7. PubMed ID: 23471307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia.
    Winestone LE; Getz KD; Miller TP; Wilkes JJ; Sack L; Li Y; Huang YS; Seif AE; Bagatell R; Fisher BT; Epstein AJ; Aplenc R
    Am J Hematol; 2017 Feb; 92(2):141-148. PubMed ID: 27862214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial.
    Hyakuna N; Hashii Y; Ishida H; Umeda K; Takahashi Y; Nagasawa M; Yabe H; Nakazawa Y; Koh K; Goto H; Fujisaki H; Matsumoto K; Kakuda H; Yano M; Tawa A; Tomizawa D; Taga T; Adachi S; Kato K
    Pediatr Blood Cancer; 2019 Oct; 66(10):e27875. PubMed ID: 31309713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: a report from the Children's Cancer Group.
    Sievers EL; Lange BJ; Sondel PM; Krailo MD; Gan J; Liu-Mares W; Feig SA
    J Clin Oncol; 1998 Mar; 16(3):914-9. PubMed ID: 9508173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors associated with 30-day all-cause hospital readmission after tracheotomy in pediatric patients.
    Yu H; Mamey MR; Russell CJ
    Int J Pediatr Otorhinolaryngol; 2017 Dec; 103():137-141. PubMed ID: 29224755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
    Lamba JK; Chauhan L; Shin M; Loken MR; Pollard JA; Wang YC; Ries RE; Aplenc R; Hirsch BA; Raimondi SC; Walter RB; Bernstein ID; Gamis AS; Alonzo TA; Meshinchi S
    J Clin Oncol; 2017 Aug; 35(23):2674-2682. PubMed ID: 28644774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparable on-therapy mortality and supportive care requirements in Black and White patients following initial induction for pediatric acute myeloid leukemia.
    Li Y; Newton JG; Getz KD; Huang YS; Seif AE; Fisher BT; Aplenc R; Winestone LE
    Pediatr Blood Cancer; 2019 Apr; 66(4):e27583. PubMed ID: 30585685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
    Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
    J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study.
    Taga T; Shimomura Y; Horikoshi Y; Ogawa A; Itoh M; Okada M; Ueyama J; Higa T; Watanabe A; Kanegane H; Iwai A; Saiwakawa Y; Kogawa K; Yamanaka J; Tsurusawa M
    Pediatr Blood Cancer; 2011 Jul; 57(1):36-40. PubMed ID: 21557456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.